Details of the Drug Combinations

General Information of This Drug (ID: DMTV4L0)

Drug Name

Myricetin DMTV4L0

Synonyms

myricetin; 529-44-2; Cannabiscetin; Myricetol; Myricitin; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one; 3,3',4',5,5',7-Hexahydroxyflavone; 3,5,7,3',4',5'-Hexahydroxyflavone; UNII-76XC01FTOJ; NSC 407290; CCRIS 5838; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one; EINECS 208-463-2; NSC407290; CHEMBL164; NSC-407290; BRN 0332331; 76XC01FTOJ

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Myricetin + Panobinostat	DC1Z58O	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Myricetin + Idarubicin	DC64XYH	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
------------------------------------------------------------------------------------

References

1	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.